Steatosis News and Research

RSS

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

Genetic analysis of 1 million people points to FNIP1 as a promising metabolic target

Mega-scale exome sequencing of 1,032,116 people identified 59 independent genes linked to the TG:HDL ratio, including 44 rare-coding associations not detected in the previous largest analysis. Ultra-rare FNIP1 loss-of-function variants were associated with favorable fat distribution, lower liver fat and glycemia, and around 60% lower odds of a composite cardiometabolic disease outcome.

7 Aug 2026

Daily tomatoes lowered a key marker of liver fat in MASLD trial

An exploratory randomized trial found that 200 g of raw tomatoes plus 50 g of tomato sauce daily for six weeks produced a greater reduction in CAP-defined hepatic steatosis than a tomato-free diet in adults with MASLD. The improvement occurred without major weight or metabolic changes, but larger and longer trials are needed to confirm its clinical significance.

2 Aug 2026

Lifestyle changes improve MASLD by suppressing key molecular pathway

Lifestyle modification is the cornerstone of managing metabolic dysfunction-associated steatotic liver disease (MASLD), a growing cause of chronic liver disease worldwide.

23 Jul 2026

Study tests chronotype’s liver link and finds no significant association

Researchers found no significant association between chronotype and FibroScan-derived liver fat or stiffness in 119 medication-naïve adults with overweight or obesity. The exploratory findings cannot exclude smaller effects, particularly for fibrosis, and require confirmation in larger longitudinal studies.

21 Jul 2026

Updated ABCs framework gives clinicians a clearer path to prevent heart disease

A 2026 State-of-the-Art review updates the ABCs of cardiovascular disease prevention to help clinicians apply contemporary risk assessment, lifestyle, pharmacologic, and cardiometabolic strategies in routine care. The framework emphasizes PREVENT™ risk equations, Life’s Essential 8, CKM syndrome, obesity care, lipid lowering, blood pressure control, healthy aging, heart failure prevention, and atrial fibrillation management.

7 Jul 2026

Fatty liver disease fuels aggressive metastatic colorectal cancer spread

Researchers at VIB and KU Leuven, with international partners, have uncovered how fatty liver disease can fuel the most aggressive form of metastatic colorectal cancer.

1 Jul 2026

Review outlines how donor imaging improves liver transplantation outcomes

Liver transplantation often depends on decisions made under pressure. In deceased donation, teams must quickly judge whether a liver is suitable, whether fat accumulation could threaten graft function, and whether unexpected vascular anatomy may complicate procurement or implantation.

22 Jun 2026

Novel RNA modification mechanism drives metabolic fatty liver disease progression

Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with a complex pathogenesis. Although epitranscriptomic modifications such as N6-methyladenosine (m6A) have been implicated in NAFLD, the role of N1-methyladenosine (m1A) and its regulators is largely unexplored.

25 May 2026

Fatty liver disease linked to higher risk of heart attacks

Researchers at Mass General Brigham Heart and Vascular Institute found that people with hepatic steatosis, commonly called "fatty liver disease," have a higher amount of noncalcified, rupture-prone coronary plaque and face nearly twice the rate of cardiovascular events compared to those without steatosis.

20 May 2026

Specific intestinal fungi play role in the pathogenesis of MASLD and cardiovascular disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for cardiovascular disease (CVD). While gut bacteria have been linked to CVD, the role of intestinal fungi in subclinical coronary atherosclerosis (SCA) remains unclear.

23 Apr 2026

Prediabetes leaves lasting fat tissue changes after bariatric surgery

Prediabetes may leave a lasting molecular "footprint" on adipose (fat) tissue which appears to make maintaining weight loss after bariatric surgery more difficult, according to new research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

22 Apr 2026

Eating oranges daily may shift lipid patterns in fatty liver disease

A 4-week trial on 'Navelina' oranges shows potential effects on lipid metabolism in fatty liver disease, revealing intriguing but non-significant patterns.

20 Apr 2026

Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global public health challenge with rapidly rising prevalence, especially in China. Despite advances in treatment, the underlying molecular mechanisms remain incompletely understood. A new research article published in the Chinese Medical Journal on March 16, 2026, provides critical insights into the role of exosomal microRNAs (miRNAs) in MASLD pathogenesis.

17 Apr 2026

Prickly pear may pack a surprising punch against metabolic syndrome

This narrative review examines how Opuntia ficus-indica fruit, or prickly pear, may help target multiple features of metabolic syndrome through its fiber, betalains, polyphenols, carotenoids, and other bioactive compounds. The authors conclude that the fruit shows promising mechanistic and preclinical potential, but stronger human trials are still needed before firm clinical claims can be made.

6 Apr 2026

New algorithm enables precise subtyping of metabolic liver disease

Metabolic-associated steatotic liver disease (MASLD) is a clinically heterogeneous condition with highly variable outcomes affecting more than 30% individuals globally.

26 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

Low testosterone and high fructose intake can worsen fatty liver disease

Low testosterone in itself can cause a variety of health problems, but the addition of a poor diet can exacerbate certain conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one example that approximately 40% of adult men worldwide currently suffer from and has become a global problem.

11 Mar 2026